aboutus_david_segarra
David Segarra
MSc, MBA

Co-Founder & CEO
David, an aptamer technology entrepreneur, co-founded aptaTargets in 2014 and has led the company to bring ApTOLL to the clinic. Previously, he was the co-founder and CEO of Aptus Biotech, an aptamer platform focused on therapeutic and diagnostic applications. aptaTargets is a spinout from Aptus Biotech. David co-founded and was General Manager of Igen, where he led the research, development, and marketing of genetic and epigenetic kits for clinical use. David has been an innovation strategy advisor for various medical institutions, an associate consultant at the international management consulting firm Arthur D. Little, and a project manager at Acciona (global energy & infrastructure firm). David holds an MBA from the IESE Business School and the University of California Berkeley, a specialty program in Business Biotechnology and an MSc. in Engineering from Barcelona Tech (UPC).

aboutus_eugenia_zarabozo
Mª Eugenia Zarabozo

Co-Founder & CFO
Maria Eugenia has been Co-founder and operations manager at Aptus Biotech (therapeutic and diagnostic applications based on aptamers), CLO at Igen Biotech (Genetic and Epigenetic kits) and partner and advisor of the investing platform Growth Factor Biocapital. Has also been advisor of the Hospital Puerta de Hierro Biomedical Research Foundation, in Madrid. She has deep expertise in financing biotechnology firms, especially with non-dilutive funds, raising an approximate amount of € 4,5 m for the 3 different companies. Maria Eugenia is also expert in licensing and intellectual property rights. Maria owns a Law degree and a Master in Business Biotechnology.

 

aboutus_macarena_hernandez
Macarena Hernández
PhD

CSO
Macarena is a professor in the Neurovascular Research Unit at University Complutense, with more than 15 years of scientific experience in neuroscience and pharmacology for cerebrovascular diseases. She is involved in several basic and applied research activities in the stroke field and completed a six-year post-doctoral period in Stroke National Investigation Consortium (INVICTUS). Macarena has collaborated with the Ramón y Cajal and the 12 Octubre hospitals in the evaluation of preclinical studies in neuroscience and the implementation of translational research units. She has a PhD in Biomedicine and Masters in Neuropsychology and Pharmacovigilance.

aboutus_marc_ribo
Marc Ribó
MD, PhD

CMO
Marc is an Assistant Professor in the Stroke Unit at the Hospital Vall d’Hebron, focusing on cerebrovascular diseases with a special interest in the acute phase of ischemic stroke and promoting systemic or endovascular reperfusion treatments. His research activity in the acute phase of stroke includes a focus on the design of clinical trials and research projects. Marc has over 200 peer-reviewed publications. His research activities also include the development of telemedicine solutions to increase and accelerate access to the best therapies for all acute stroke patients. Marc holds a neurology degree from the Hospital Vall d’Hebron, a PhD in Medicine at Universitat Autonoma de Barcelona, and conducted a Stroke Fellowship at the University of Texas Houston.

MARIAN REVIRIEGO
Marian Reviriego
MBA, MSc

Regulatory Affairs
Marian worked at the Medicine and Healthcare products Regulatory Agency (MHRA) in the UK as a Pharmaceutical Assessor of registration dossiers. She has worked at pharmaceutical and biopharmaceutical companies including Pharma Mar, Chemo, and TiGenix (currently Takeda). Marian holds a Pharm Degree, a Master in Regulatory Affairs, and an MBA.

MARCO_PUGLIESE
Marco Pugliese
PhD

Clinical Operations Manager
Marco was the co-founder and CEO of Neurotec Pharma, where they developed treatments for CNS diseases mainly related to inflammation and neurodegeneration. He was a Business Development Manager at the Research Institute of Vall d’Hebron (VHIR, Spain) and Director of the Spanish node of EIT Health. Marco holds a PhD in Neuroscience from the University of Barcelona and a bachelor’s degree in Veterinary Medicine from the University of Perugia in Italy.

aboutus_david_pineiro
David Piñeiro
PhD

PM & CMC
David has worked for international institutions including the Apoptotic Center Research Unit of CHEO Research Institute in Ottawa, Canada, and the MRC Toxicology Unit in Leicester, United Kingdom, where he successfully led international and collaborative projects related to apoptosis, aptamers, and characterization of the oligonucleotide-protein interactions to identify potential therapeutic targets. He has spent more than 15 years working on molecular biology and cell signaling projects, focusing on gene expression, protein synthesis regulation, and its functionality. David holds a PhD in Biochemistry and Molecular Biology.

David Saxner 2
David Saxner

Business Development
David has worked as a life science consultant at Longfellow Associates and for Gel4Med and Bioimag both of which were Harvard Innovation Lab companies. He has worked with CEOs to develop corporate strategy, business operational systems, and strategic relationships. David started as a formulations process development engineer at Shire Pharmaceuticals. He holds a Bachelor degree in Chemical Engineering from Worcester Polytechnic Institute.  

aboutus_david_segarra
David Segarra
MSc, MBA

Co-Founder & CEO
David, an aptamer technology entrepreneur, co-founded aptaTargets in 2014 and has led the company to bring ApTOLL to the clinic. Previously, he was the co-founder and CEO of Aptus Biotech, an aptamer platform focused on therapeutic and diagnostic applications. aptaTargets is a spinout from Aptus Biotech. David co-founded and was General Manager of Igen, where he led the research, development, and marketing of genetic and epigenetic kits for clinical use. David has been an innovation strategy advisor for various medical institutions, an associate consultant at the international management consulting firm Arthur D. Little, and a project manager at Acciona (global energy & infrastructure firm). David holds an MBA from the IESE Business School and the University of California Berkeley, a specialty program in Business Biotechnology and an MSc. in Engineering from Barcelona Tech (UPC).

aboutus_eugenia_zarabozo
Mª Eugenia Zarabozo

Co-Founder & CFO
Maria Eugenia has been Co-founder and operations manager at Aptus Biotech (therapeutic and diagnostic applications based on aptamers), CLO at Igen Biotech (Genetic and Epigenetic kits) and partner and advisor of the investing platform Growth Factor Biocapital. Has also been advisor of the Hospital Puerta de Hierro Biomedical Research Foundation, in Madrid. She has deep expertise in financing biotechnology firms, especially with non-dilutive funds, raising an approximate amount of € 4,5 m for the 3 different companies. Maria Eugenia is also expert in licensing and intellectual property rights. Maria owns a Law degree and a Master in Business Biotechnology.

 

aboutus_pablo_cironi
Pablo Cironi
PhD

Director of Life Science Investment Funds, Caixa Capital Risc. Board Member
Pablo Cironi is the Director of Life Science Investment Funds at Caixa Capital Risc. He focuses on investment in therapeutics and medical devices. Pablo has more than 12 years of experience in business development, technology transfer and in early stage investment. Pablo graduated in Chemistry from the University of Buenos Aires, and holds a Ph.D. in Organic Chemistry from the University of Barcelona. From 2005 to 2009, he was a postdoctoral Fulbright Fellow at the Department of Systems Biology at Harvard University.

aboutus_sara_secall
Sara Secall
MBA, MSc

Investment Director of Inveready’s Biotechnology Fund. Board Member
Currently Investment Director of Inveready’s Biotechnology Fund, where she screens, invests and manages investments in Drug Development, Molecular Diagnostics, Nutraceuticals and Medical Devices. Previously, was Director of Spin-outs for the University of Barcelona, where she helped launch and finance over 25 start-ups and negotiated numerous technology licenses. Prior experience includes working as an analyst for Chevron Technology Ventures, the Corporate Venture Capital Fund of the US’s second largest integrated oil company, with US 210 Million under management, where she was involved in investing and successfully exiting energy-related technology start-ups. Also worked for Dames and Moore (now URS Corp), the environmental consultancy firm, in the US, Canada and Latin America as well as the World Bank and the International Finance Corporation. Sara holds a BS in Chemistry from the University of Barcelona, a Master’s in Environmental Science from Indiana University, and an MBA from the London Business School.

aboutus_mads_dalsgaard
Mads Dalsgaard
MD, DMSc, MBA

Independent Board Member
Currently, Senior-Vice President of Experimental Medicine & Clinical Development at Lundbeck, covering Clinical Pharmacology (phase I), PK/PD modelling & simulation, translational biomarkers, global Clinical Research I-II-III-IV within therapeutic areas of psychiatry, neurology and paediatrics and Clinical Operations as well as statistics, data analysts, epidemiology, data management and bioinformatics. Member of corporate Portfolio Management, R&D Leadership, Chairs Clinical Research Committee, member of Business Development and In-licensing Committee, among other activities. Previously, has been General Manager & Representative Director of Lundbeck Japan, Head of Medical Affairs (neurology), Executive assistant to the EVP for Research & Development, Head of the Stroke Section for global clinical development programs in stroke and neurodegenerative diseases. Mads is Medical Doctor from Copenhagen University, holds a Doctoral thesis (DMSc/dr.med.) on human brain metabolism and blood flow, and an MBA from the Institute of Management Development (IMD), Lausanne.

ignacio_lizasoain
Ignacio Lizasoain
MD, PhD

Medical Doctor and Head of the Department of Pharmacology of the Universidad Complutense School of Medicine, in Madrid. Leads the Neurovascular Research Unit, a research institution devoted to the study of cerebrovascular disease.

victor_gonzalez
Víctor Manuel González
PhD

Leads the Aptamer Group at the Ramón y Cajal Institute for Health Research (IRYCIS) focused on the selection and characterization of aptamers to be used in the development of diagnostic systems and/or therapeutic. In 2010 he co-founded Aptus Biotech and is currently the company’s COO.

joaquin_casariego
Joaquín Casariego
MD, MBA

Has 16 years of experience as Medical Officer in the pharma industry. Has been European Medical Director in Urology at Eli Lilly, Global Medical Director in the Urology Center of Excellence at GlaxoSmithKline, Medical Affairs Director EMEA (Prostate cancer) at Janssen.

bernd_jilma
Bernd Jilma
MD, PhD

Professor of Clinical Pharmacology & Internal Medicine at the Medical Univ. of Vienna. Head Division of Hematology and Immunology and Vice-Chair of Department of Clinical Pharmacology. Expert to the EMA with relevant roles in the past as a member in the Committee for Orphan Medicinal Products (COMP) and the Committee of Advanced Therapies.

ian_cotgreave
Ian Cotgreave
PhD

Professor of Toxicology at the Karolinska Institute. Has been Head of AstraZeneca’s Molecular Toxicology unit in Global Safety Assessment and Responsible for front-loading safety predictions in all drug projects, assisting over 100 INDs to clinical studies.

gustavo_vitale
Gustavo Vitale
MD, MBA

Experienced Medical Affairs professional, specialized in Cardiovascular. Medical Lead of CVRM at AstraZeneca (2014-2020); Associate Director Medical Affaires Cardiovascular and Atherosclerosis at MSD (2007-2014); LATAM manager at startup NxTrial Corp (New Jersey, USA).

marco_moreno
Marco Moreno
PhD

Brings over 20 years in the pharmaceutical industry with a broad experience in all the Chemistry, Manufacturing and Control (CMC) and Quality aspects from preclinical to commercial development across multiple indications. Has worked in key role positions at QualitecFarma and Pfizer.

thomas_rupp
Thomas Rupp

Trained chemist, worked with oligonucleotide manufacturing for more than 30 years, including development of “state-of-the-art” manufacturing processes for all kinds of oligonucleotides. Has worked at the DKFZ-Heidelberg, Innovir, Noxxon, GE Healthcare and Girindus.